ArticleJournal of cardiothoracic surgery2026
Identification of PANoptosis-related hub genes in acute myocardial infarction: diagnostic potential, immune correlates, and therapeutic insights.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPANoptosis is an innate immune-inflammatory programmed cell death pathway that integrates the key features of apoptosis, pyroptosis, and necroptosis. However, the diagnostic potential and immune relevance of PANoptosis-related genes in acute myocardial infarction (AMI) remain unclear.
methodsTranscriptional data were obtained from the GEO database, including the training set GSE66360 and validation set GSE59867. Differential expression, protein-protein interaction networks, and random forest analyses were conducted to identify PANoptosis-related hub genes associated with AMI pathogenesis. The diagnostic model and nomogram were built, and the diagnostic value was evaluated using receiver operating characteristic analysis. Immune infiltration, functional enrichment, and regulatory network analyses were performed to explore potential molecular mechanisms. Blood samples from healthy controls and AMI patients were collected to validate the expression of hub genes.
resultsA total of 438 DEGs and 109 PANoptosis-related genes were obtained. After intersecting these, 8 PANoptosis genes associated with AMI were found, enriched in apoptosis, immune, and inflammatory pathways. Two hub genes, IL1B and NLRP3, were identified as hub genes, with diagnostic models and nomograms showing good performance in both training and validation sets. These genes were significantly correlated with most immune cells that were dysregulated in AMI, revealing their immunomodulatory function. CEBPB and SPI1 were identified as common transcriptional regulators of the hub genes. Five drugs associated with hub genes were predicted from the DSigDB database. IL1B and NLRP3 showed consistent expression patterns across the training set, validation set, and real-time qPCR analysis.
conclusionIL1B and NLRP3 may serve as PANoptosis-related biomarkers with potential immunomodulation in AMI, offering preliminary insights into the potential molecular mechanisms of PANoptosis in AMI.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.